By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

The company is also navigating activist criticism over access to Yeztugo and ongoing negotiations with Gilead, even as U.S.

Eli Lilly plans to increase prices of medicines in Europe and other developed markets “in order to make them lower” in the ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Retailers in the U.S. are increasingly cautious due to tariffs and destocking inventories as cost-conscious consumers tighten ...

Amazon extended its lead in the U.S. e-commerce market in the second quarter, according to JPMorgan (NYSE:JPM), which cited the company’s accelerating retail growth and logistics advantages.

Industries to Neutral from Buy after the building materials company reported weaker quarterly earnings and lowered its guidance on North America, its largest market.